Cardiovascular risk associated with first-line Janus kinase inhibitors versus TNF inhibitors in patients with RA: a nationwide cohort study

Clicks: 18
ID: 332564
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #165 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective To compare the risk of major adverse cardiovascular events (MACE) between tumor necrosis factor inhibitors (TNFi) and Janus kinase inhibitors (JAKi) when initiated as first-line advanced therapy in patients with rheumatoid arthritis (RA). Methods Using the Korean nationwide claims database, we identified patients newly diagnosed with RA between 2010 and 2015. Patients who initiated TNFi or JAKi as first-line advanced therapy were selected for analysis. Patients were followed from initiation of TNFi or JAKi through June 2024. The primary outcome was incident MACE, defined as myocardial infarction, ischemic stroke, or coronary revascularization. Multivariable Cox proportional hazards models were applied in the total cohort. We additionally performed propensity score (PS)–matched analyses to address confounding by indication. Prespecified subgroup analyses were conducted according to baseline cardiovascular risk factors. Results The study included 6,174 patients (TNFi = 5,152; JAKi = 1,022). The incidence rates of MACE were 4.1 and 3.6 per 1,000 person-years in the TNFi and JAKi groups, respectively. MACE risk did not differ significantly between JAKi and TNFi in the total study cohort (adjusted hazard ratio [HR] 0.636, 95% confidence interval [CI] 0.283 to 1.429) or in the PS-matched population (adjusted HR 0.715, 95% CI 0.187 to 2.739). Results were consistent across all prespecified subgroups, including patients with baseline cardiovascular risk factors. Conclusion First-line use of JAKi was not associated with an increased risk of MACE compared with TNFi. These findings provide real-world evidence supporting the cardiovascular safety of JAKi as first-line advanced therapy in patients with RA.
Reference Key
openalex_W7222719591 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Oh Chan Kwon, Hye Sun Lee, So Young Jeon, Min-Chan Park
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag582
URL
https://doi.org/10.1093/rheumatology/keag582
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.